Exploring EVKEEZA (evinacumab-dgnb)
Friday, May 30, 2025 | 11:00 - 11:50 am
Speaker: James Trippi, MD, FNLA
Early detection and intervention in HoFH* Mechanism of action for EVKEEZA* Clinical efficacy and safety of EVKEEZA*myRARE: Patient support for EVKEEZA* 48 week study (24 week double-bline treatment period followed by 24-week open-lable treatment period).
Sponsored by Regeneron Pharmaceuticals | Lunch provided by the NLA
Utilizing Coronary CTA and HeartFlow to Diagnose and Guide Management of CAD
Saturday, May 31, 2025 | 8:00 - 8:50 am
Sponsored by Heartflow | Breakfast provided by the NLA
TBA
Saturday, May 31, 2025 | 8:00 - 8:50 am
Sponsored by Chiesi Global Diseases | Breakfast provided by the NLA
Breaking New Ground: The First FDA-Approved Treatment for Clinically Diagnosed FH patients with Elevated Lp(a)
Saturday, May 31, 2025 | 12:00 - 12:50 pm
Sponsored by Kaneka Medical America, LLC | Lunch provided by the NLA
TBA
Saturday, May 31, 2025 | 12:00 - 12:50 pm
Sponsored by the Ionis Pharmaceuticals | Lunch provided by the NLA